VIP Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 8 to 12 weeks on, followed by 4 weeks off; an 8-weeks-on, 8-weeks-off pattern is also used
• Frequency: Once or twice daily; some clinic-style protocols run five days per week
• Common delivery routes: Subcutaneous injection, intranasal spray
• Key timing notes: Morning or early afternoon administration is standard; avoid late-day dosing to minimize potential interference with sleep

Who This Protocol Is For

VIP draws a notably broad range of users, and the protocols vary considerably by goal. Understanding that range is the starting point for understanding why no single VIP protocol fits everyone.

The most concentrated community of VIP users is people dealing with complex, hard-to-treat inflammatory conditions, particularly chronic inflammatory response syndrome (CIRS) from mold or biotoxin (a toxin produced by mold or bacteria) exposure, long COVID, and ME/CFS (a chronic fatigue condition). For these users, VIP is not a general wellness tool. It is a targeted intervention aimed at resolving ongoing inflammatory dysregulation, supporting grey matter integrity, and restoring baseline function after prolonged illness.

A second group uses VIP for respiratory and circulatory support. VIP's bronchodilatory (widening the airways to ease breathing) properties make it relevant for people managing airway reactivity, and its vasodilatory action has drawn interest from users dealing with conditions like Raynaud's disease, where circulation is the primary problem.

A third group represents more general use: immune modulation, gut health support, and anti-inflammatory support in the context of joint or metabolic health. These users typically run shorter, more conservative cycles focused on maintaining baseline without targeting a specific condition.

Delivery method preference matters here more than with most peptides. Subcutaneous injection offers more direct systemic exposure, while intranasal spray is preferred for pulmonary and neurological applications and for users managing needle aversion. Both routes are genuinely supported and neither is a lesser option. The route a user chooses shapes timing, frequency, and what to expect across the cycle, so it is a real protocol variable from the start.

How Is a VIP Cycle Structured?

A VIP cycle follows a titration-to-maintenance model. Because VIP does not accumulate in the body, there is no pharmacological case for a traditional loading phase. Instead, the cycle opens with a conservative titration period, gives the body time to respond, then settles into a steady maintenance rhythm for the bulk of the run.

The cycle typically runs 8 to 12 weeks on the active protocol, followed by a break of roughly 4 weeks. An alternative pattern used in the community runs 8 weeks on and 8 weeks off, which allows more complete resensitization of the VPAC receptors (the cell surface proteins that VIP binds to and activates) between cycles. For complex conditions like CIRS or long-term mold illness, some users maintain VIP use over months to years under clinical supervision, though that context is distinct from the standard research protocol.

Within an active cycle, the structure is straightforward: a brief initial titration period of 1 to 2 weeks where the user starts conservatively and assesses tolerance, followed by the maintenance phase where the dose stabilizes at the lowest level that produces a meaningful response. The goal throughout is consistent, predictable receptor engagement using divided daily dosing. The off-cycle break, whether 4 weeks or 8, serves one primary purpose: allowing those VPAC receptors to fully resensitize before the next cycle begins. The full mechanics of each phase are covered in the Loading and Maintenance Phases section below.

VIP is not FDA-approved for human use, and all compounded and research-grade formulations fall outside formal regulatory approval for the applications described here. Athletes subject to WADA testing should verify current classification status independently.

How Your Dose Is Determined

What moves a VIP dose:

• Your goal: VIP is run for a wide range of goals, and the dose reflects that range. General immune modulation and gut support sit toward the lower end of the range, with conservative once-daily dosing common in early use. Respiratory support and anti-inflammatory applications tend to sit in the middle of the range, often using twice-daily dosing. Complex inflammatory conditions like CIRS or long COVID are associated with the upper range of protocols, with doses ramped up gradually over weeks or months.
• Experience level: Users new to VIP consistently start at the conservative end and titrate upward over 1 to 2 week assessment windows. More experienced users or those under clinical supervision may begin at a higher point within the range, though the titration principle still applies.
• Delivery route: Subcutaneous injection and intranasal spray do not use the same dose or frequency. The intranasal route requires multiple sprays across the day to achieve comparable systemic exposure, and the number of sprays varies considerably by goal. The two routes are not interchangeable on a one-to-one basis.
• Individual response: VIP's vasodilatory effects show up quickly in many users, with flushing and warmth soon after dosing. Those responses are a real-time signal about how the body is responding, and they inform whether the dose holds, rises, or adjusts. Two people with the same goal may land at different points in the range based on how much vasodilatory effect they experience and tolerate.

VIP's ultra-short biological half-life, measured in minutes, means the body clears it almost as fast as it arrives. That fact explains why divided daily dosing is standard: a single daily administration leaves long stretches where VIP's receptor targets go unstimulated. Splitting the daily dose into two administrations maintains more consistent receptor engagement throughout the day. There is no single dose that fits everyone running a VIP protocol. The goal, the route, and the individual response together determine where on the range makes sense, and those are exactly the variables the Protocol Creator personalizes.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal, your delivery route (subcutaneous or intranasal), and whether you dose once or twice daily and builds your VIP protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take VIP?

Frequency is one of the most important protocol decisions for VIP, and the reason is pharmacokinetic. VIP's biological half-life is approximately 1 to 2 minutes in plasma. The peptide is cleared from the bloodstream almost immediately after administration. Think of it like pouring water into a bucket with a hole in the bottom: each dose creates a short burst of activity, and consistent re-dosing is the only way to maintain steady receptor engagement throughout the day.

That reality drives frequency decisions across all protocols. Once-daily dosing is used in conservative starting protocols and general wellness applications, where the goal is a daily signal rather than sustained engagement. Twice-daily dosing, typically spaced about 12 hours apart, is the most frequently cited research protocol for users targeting immune modulation, respiratory support, or inflammatory management. A five-days-per-week pattern appears in some clinic-style protocols, particularly at higher individual doses.

Timing within the day matters for VIP more than for many peptides. VIP plays a natural role in regulating the body's internal 24-hour clock, and endogenous VIP levels follow a diurnal pattern tied to light exposure and waking cycles. Administering in the morning or early afternoon aligns with that natural rhythm and avoids potential interference with sleep that later dosing might cause.

For intranasal spray users, the frequency structure is similar in principle but different in mechanics. Multiple sprays across the day are standard, with some protocols distributing doses across four daily windows to maintain consistent exposure at both the nasal tissue and systemic levels.

Loading and Maintenance Phases

VIP does not use a loading phase in the traditional sense. A conventional loading phase relies on a compound accumulating in the body over the first few days to establish a baseline concentration. VIP's plasma half-life makes that strategy pharmacologically irrelevant: the compound is gone within minutes of each dose, so there is nothing to accumulate.

What the cycle does have is a titration period that serves a functionally similar purpose. During the first 1 to 2 weeks, the user starts at the conservative end of the range for their goal and delivery route, administers consistently, and monitors response, particularly the vasodilatory effects like flushing and blood pressure changes. The titration period is not about building a reservoir. It is about confirming the dose is appropriate before the protocol commits to it.

Once the assessment period is complete, the protocol either holds at the starting level if the response is adequate, or adjusts upward in a single measured increment before reassessing. This transition marks the beginning of the maintenance phase: the dose that produces a meaningful response at the lowest effective level, held consistently for the remainder of the active cycle. The goal is not escalation. It is stability.

Some practitioners and community users incorporate a brief 48 to 72 hour drug holiday mid-cycle during long runs. This is not an off-cycle. It is a short planned pause designed to allow partial VPAC receptor resensitization during an otherwise continuous protocol. If VIP is showing diminishing effects in the later weeks of a cycle, a brief structured pause is the first adjustment most protocols call for, not a dose increase.

Off-Cycle Considerations

VIP does not accumulate between doses. Because it is enzymatically cleared within minutes of each administration, there is no compound buildup that would mandate a break for safety reasons the way some longer-acting peptides do. The off-cycle rationale for VIP is receptor-based, not toxicity-based.

The VPAC receptors that VIP acts on can desensitize with continuous stimulation. When receptor sensitivity diminishes, the same dose produces less effect. A break allows those receptors to resensitize so the next cycle delivers its full effect again from the start.

The most widely cited formal protocol runs approximately 12 weeks on followed by 1 month off. This maps well to the typical benefit timeline, where significant effects in respiratory function and immune regulation are reported in the 8 to 12 week window. The 4-week break gives the system a meaningful recovery period without losing progress built during the on-cycle. An 8-weeks-on, 8-weeks-off pattern is also used, particularly in community protocols focused on grey matter support and cognitive function.

For users managing complex chronic inflammatory conditions, some clinical contexts involve very long continuous use under professional supervision, with breaks determined by clinical response rather than a fixed schedule. Continuous use without a planned break is not automatically contraindicated, but most sources recommend monitoring for signs of diminishing response as the signal to introduce one.

What to Expect Week by Week

• Week 1 to 2: The most commonly reported early effect is a vasodilatory response, typically a warm or flushed sensation that arrives soon after administration and resolves within about 10 minutes. For users targeting respiratory function, early improvements in breathing ease are frequently reported in this window. Some users notice reduced brain fog. Effects at this stage are often tied to the immediate post-dose window rather than sustained throughout the day.
• Week 3 to 4: The vasodilatory response tends to settle as the body adjusts. Users in this range commonly report improvements in gut health markers, reduced bloating, and fewer airway restrictions. For users managing inflammatory conditions, immune regulation effects begin to emerge. This is also the primary assessment window for titration decisions.
• Week 5 to 8: More meaningful structural effects become evident for users targeting respiratory and joint health. Fewer breathlessness episodes are commonly reported. Users in CIRS or mold illness protocols often describe this as the phase where effects feel more stable and less acute.
• Beyond 8 weeks: For complex inflammatory applications, quality-of-life improvements and cognitive clarity gains are most consistently reported in this window. Support for the body's internal clock, digestive health stabilization, and sustained energy improvements appear in protocols here.

These are commonly reported ranges drawn from published research and real-world protocol data, not guarantees. Individual results vary considerably by goal, route, consistency of administration, and individual response. For users managing CIRS or long COVID, the timeline can extend well beyond 12 weeks before full benefits are established.

For someone running a well-structured VIP cycle targeting immune modulation and respiratory support, the arc commonly reported looks like this: early vasodilatory effects that moderate over the first few weeks, growing ease of breathing and reduced systemic inflammation through weeks 3 to 8, and measurable improvements in energy and quality of life by week 12. Dosed consistently and titrated thoughtfully, that progression is what the research and community protocols most frequently describe.

Common Protocol Mistakes

Starting too high. VIP's vasodilatory mechanism means too much, too soon produces significant flushing, lightheadedness, and hypotension. The conservative titration model exists for a reason. Users who bypass it and open with an aggressive dose often experience side effects that push them off the protocol entirely, even when a lower starting point would have been well tolerated.

Ignoring the half-life. VIP clears from plasma in approximately 1 to 2 minutes. Dosing once daily and expecting sustained effect throughout the day is a mismatch between biology and protocol design. The short half-life is the primary reason divided daily dosing is standard. Once-daily use is appropriate for conservative starting protocols, but users expecting the same sustained coverage as twice-daily dosing will be disappointed.

Inconsistent administration. VIP's effects are tied to consistent receptor engagement rather than compound accumulation. Irregular dosing makes it nearly impossible to assess whether the protocol is working. The 1 to 2 week assessment windows that guide titration decisions only mean something if administration has been consistent throughout.

Improper reconstitution. Unit confusion between mg and mcg, and between mL and units on an insulin syringe, is one of the most frequently reported errors in injectable peptide use, and VIP is no exception. Getting the math wrong can mean dosing at ten times the intended amount or one-tenth of it. Reconstitution math belongs in the MyPeptidePal Protocol Creator, which handles vial size, water volume, and concentration calculations so this step is not left to guesswork.

Poor storage. Once reconstituted, VIP requires refrigeration and protection from light. A degraded peptide produces inconsistent effects, and the degradation is invisible to the user. A protocol that appears to be failing may simply be running on compromised product.

Consuming alcohol during the protocol. Alcohol activates hepatic enzymes that degrade VIP, reducing its bioavailability significantly. Users who drink regularly during a VIP cycle are undermining the protocol at a biochemical level.

Not monitoring blood pressure. VIP's vasodilatory effects can lower blood pressure meaningfully, particularly in users who trend toward lower baseline readings or who take antihypertensive medications. Orthostatic hypotension on standing quickly after injection is among the more common early adverse effects. Regular blood pressure checks, especially during the titration period, are standard across clinical protocols.

Frequently Asked Questions

How long is a typical VIP cycle?

The most widely cited formal protocol runs approximately 12 weeks on followed by a 4-week break. An 8-weeks-on, 8-weeks-off pattern is also used, particularly in community protocols focused on cognitive and grey matter support. Individual cycle length depends on the goal and clinical response, and is personalized in the MyPeptidePal Protocol Creator.

How often do you take VIP?

Most research protocols use once or twice daily dosing, with twice-daily administration typically spaced about 12 hours apart being the most common pattern for immune modulation and inflammatory support. Some clinic-style protocols run five days per week rather than daily. VIP's extremely short plasma half-life is the primary reason divided daily dosing is standard rather than a single daily administration.

Does VIP need a loading phase?

No. VIP's plasma half-life makes a traditional loading phase pharmacologically unsupported. The compound clears before it can accumulate, so there is nothing to load. VIP protocols use a titration period in the first 1 to 2 weeks instead, starting conservatively and assessing response before settling into a stable maintenance dose.

Do you need to cycle off VIP?

A formal off-cycle break is not universally required, but most protocols recommend one to prevent VPAC receptor desensitization. Continuous stimulation of these receptors over a long run can produce diminishing returns. A 4-week break after a 12-week cycle, or an equal-duration break after an 8-week cycle, allows the receptors to resensitize so the next cycle is fully effective.

Can VIP be taken as a nasal spray instead of injection?

Yes. Compounded intranasal VIP spray is a genuinely supported delivery route, not a lesser alternative to injection. It is particularly relevant for pulmonary and neurological applications and for users with needle aversion. The intranasal route requires multiple sprays distributed across the day rather than a single administration, and the dose differs from the injectable protocol, so the two routes are not interchangeable on a one-to-one basis.

What are the most common side effects during a VIP cycle?

Flushing and facial warmth are the most frequently reported effects, commonly reported in research and protocol data, and they typically resolve within minutes of onset. Transient low blood pressure and headache are also common, both directly related to VIP's vasodilatory mechanism. Injection site reactions including redness and tenderness have been reported in a meaningful proportion of subcutaneous users. Most side effects are mild and tied directly to the dose level, which is one of the reasons the conservative titration approach is standard.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for VIP in one place.